Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZT-12-037-01 |
Synonyms | |
Therapy Description |
ZT-12-037-01 is an ATP-competitive small molecule inhibitor, which inhibits the kinase activity of STK19, potentially resulting in increased apoptosis and reduced tumor growth (PMID: 30712867). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZT-12-037-01 | EX-A3169 | ZT-12-037-01 is an ATP-competitive small molecule inhibitor, which inhibits the kinase activity of STK19, potentially resulting in increased apoptosis and reduced tumor growth (PMID: 30712867). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61R | melanoma | sensitive | ZT-12-037-01 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ZT-12-037-01 treatment induced apoptosis and inhibited cell proliferation and colony formation in culture and reduced tumor growth and increased survival in cell line xenograft models of melanoma harboring NRAS Q61R (PMID: 30712867). | 30712867 |
BRAF V600E | melanoma | decreased response | ZT-12-037-01 | Preclinical - Cell culture | Actionable | In a preclinical study, melanoma cell lines harboring BRAF V600E demonstrated reduced inhibition of cell proliferation and induction of apoptosis compared to cells harboring NRAS Q61R in culture when treated with ZT-12-037-01 (PMID: 30712867). | 30712867 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|